[Effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome].
To investigate the effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome (PCOS). Ninety-six PCOS women with insulin resistance (IR) were randomly divided into three groups. Group A (28 cases) received clomiphene citrate (CC) alone. Group B (32 cases) received rosiglitazone alone. And group C (36 cases) received CC and rosiglitazone in combination. All were treated for three menstrual cycles. Homeostasis model assessment insulin resistance (HOMA IR) and ovulation before and after treatment were compared among the 3 groups. After the treatment, HOMA IR in group B and C decreased from 1.2 +/- 0.6 to 0.6 +/- 0.2 and from 1.1 +/- 0.5 to 0.6 +/- 0.4, respectively (P < 0.05). Success rate of ovulation after treatment in group C (80%) was higher than that in group A (59%) and group B (35%, P < 0.05). Rosiglitazone therapy improves insulin sensitivity and ovulation induction.